A secondary analysis of the phase 2 PACIFIC-STROKE trial showed that asundexian is effective for the secondary prevention of stroke in patients with stroke of atherosclerotic origin, but not those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback